Loading...

Bachem Holding AG

0QND.LLSE
Healthcare
Medical - Pharmaceuticals
£64.90
£-3.13(-4.60%)

Bachem Holding AG (0QND.L) Financial Performance & Income Statement Overview

Explore the financials of Bachem Holding AG (0QND.L), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
4.84%
4.84%
Operating Income Growth
2.84%
2.84%
Net Income Growth
7.50%
7.50%
Operating Cash Flow Growth
-41.44%
41.44%
Operating Margin
21.89%
21.89%
Gross Margin
30.16%
30.16%
Net Profit Margin
19.87%
19.87%
ROE
8.92%
8.92%
ROIC
8.07%
8.07%

Bachem Holding AG (0QND.L) Income Statement & Financial Overview

Analyze Bachem Holding AG’s 0QND.L earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$364.95M$240.31M$337.46M$239.86M
Cost of Revenue$243.32M$179.39M$219.02M$181.33M
Gross Profit$121.63M$60.92M$118.43M$58.53M
Gross Profit Ratio$0.33$0.25$0.35$0.24
R&D Expenses$4.35M$7.03M$5.55M$5.49M
SG&A Expenses$20.18M$19.06M$18.73M$18.63M
Operating Expenses$24.52M$25.54M$24.27M$24.13M
Total Costs & Expenses-$267.84M$204.92M$243.30M$205.46M
Interest Income$286000.00$849000.00$1.35M$335000.00
Interest Expense$150000.00$142000.00$149000.00$218000.00
Depreciation & Amortization$23.19M$20.07M$19.67M$17.68M
EBITDA$117.99M$55.46M$110.78M$52.50M
EBITDA Ratio$0.32$0.23$0.34$0.22
Operating Income$97.11M$35.39M$94.16M$34.40M
Operating Income Ratio$0.27$0.15$0.28$0.14
Other Income/Expenses (Net)-$2.46M$5.17M-$6.87M$2.10M
Income Before Tax$94.64M$40.56M$87.29M$36.92M
Income Before Tax Ratio$0.26$0.17$0.26$0.15
Income Tax Expense$10.55M$4.41M$9.88M$2.47M
Net Income$84.09M$36.16M$77.41M$34.45M
Net Income Ratio$0.23$0.15$0.23$0.14
EPS$1.12$0.48$1.03$0.46
Diluted EPS$1.12$0.48$1.03$0.46
Weighted Avg Shares Outstanding$74.98M$75.33M$74.97M$74.89M
Weighted Avg Shares Outstanding (Diluted)$74.98M$75.33M$74.97M$74.89M

Over the last four quarters, Bachem Holding AG achieved steady financial progress, growing revenue from $239.86M in Q2 2023 to $364.95M in Q4 2024. Gross profit stayed firm with margins at 33% in Q4 2024 versus 24% in Q2 2023. Operating income totaled $97.11M in Q4 2024, maintaining a 27% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $117.99M. Net income rose to $84.09M, with EPS at $1.12. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;